By Michael Borella and Walter DeGroft[1] –For the fifth consecutive year, we have surveyed how the Patent Trial and Appeal Board (PTAB) decides appeals of § 101 rejections from examiners. Readers of the previous installments will know the drill
Patent Docs is a specialized blog focusing on patent law and intellectual property issues, particularly in the United States. It publishes detailed analyses and commentary on patent eligibility, subject matter eligibility, patent office policies, and recent court decisions affecting patent law. The blog often discusses the impact of legal standards such as the Alice test and Section 101 on patentability, as well as regulatory developments involving the USPTO and Federal Trade Commission. It also covers topics related to pharmaceutical patents, inventorship rules, and the challenges of patenting AI-assisted inventions. The content is aimed at legal professionals, patent practitioners, and those interested in patent policy and law.
By Michael Borella and Walter DeGroft[1] –For the fifth consecutive year, we have surveyed how the Patent Trial and Appeal Board (PTAB) decides appeals of § 101 rejections from examiners. Readers of the previous installments will know the drill…
By Kevin E. Noonan –
In a nonprecedential opinion, the Federal Circuit affirmed a decision by the Patent Trial and Appeal Board that the claim challenged in an ex parte reexamination was invalid for anticipation in In re Magnolia Medical…
By Michael Borella –
More than a decade after Alice Corp. v. CLS Bank Int’l, the two-step framework for patent eligibility under 35 U.S.C. § 101 remains as contentious as ever. Courts, commentators, and the U.S. Patent and Trademark…
By Kevin E. Noonan –
The Federal Circuit affirmed a District Court determination that method claims reciting administration of a modification of an established antibiotic by adding magnesium to the composition were infringed and not invalid in Melinta Therapeutics, LLC…
By Michael Borella –
By Donald Zuhn –
The U.S. Patent and Trademark Office has published a final rule in the Federal Register (an unpublished version of the notice, which will be published on June 24, can be found here), in which the…
By Kevin E. Noonan –
In a nonprecedential decision, the Federal Circuit recently affirmed a district court’s finding that innovator drugmaker Otsuka Pharmaceutical failed to show generic competitor Lupin infringed (or would infringe, if it marketed an FDA-approved generic version…
The Supreme Court issued an Order this morning denying certiorari in Newman v. Moore. The Court’s Order states that:
The motion for leave to file a brief in opposition under seal with redacted copies for the public record is granted. …
By Kevin E. Noonan –
At the beginning of June, the New Civil Liberties Alliance (representing Judge Paulene Newman) filed the Judge’s Reply Brief to the Federal Circuit Judicial Council’s Opposition to her Petition for Certiorari*. The brief specifically identifies…
By Kevin E. Noonan –
The Judicial Council of the Federal Circuit, represented by the U.S. Solicitor General, recently filed its Respondents’ Brief in Opposition to Judge Pauline Newman’s Petition for Certiorari. While the brief followed its expected path of…